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Abstract
The main goal in curative radiation therapy is to eradicate the tumor
while minimizing radiation-induced damage to normal tissue. Ions, includ-
ing protons and carbon ions, are increasingly being used for cancer treat-
ment. They allow for a more focused dose to the tumor and exhibit higher
effectiveness in cell killing compared to conventional radiation therapy us-
ing photons. The aim of this thesis is to develop and evaluate mathematical
models for biological effect estimation with the focus on proton and light ion
irradiation.
Two radiobiological models for ions were developed. Firstly, the repairable-
conditionally repairable damage (RCR) cell survival model was extended to
account for the linear energy transfer (LET). Secondly, a model that estimates
the relative biological effectiveness (RBE) of protons based on dose, LET,
and cell type was derived. The LET-parameterized RCR model provides an
adequate fit to experimental cell survival data derived from irradiation with
carbon ions and helium ions. The RBE model predicts a cell-dependent re-
lation between RBE and LET determined by the cell-specific parameter α/β
of the linear-quadratic model of photons.
In a separate study, the effect of accounting for variable RBE in treatment
plan comparison was investigated using the proposed RBE model. Lower
RBE was predicted in the tumor and higher RBE in adjacent organs than
the commonly assumed RBE equal to 1.1. Disregarding this variation and
instead assuming RBE equal to 1.1 in treatment plan optimization may lead
to optimistic estimates for the proton plan and thereby biases treatment plan
comparison in its favor.
Derived dose-response relations of normal tissue toxicity are uncertain
because they are based on limited numbers of patients. A bootstrap method
was proposed to assess the uncertainty in clinical outcome data due to sam-
pling variability, and translate this into an uncertainty in the dose-response
relation. The method provides confidence intervals of the dose-response re-
lation, suggests model parameter values with confidence intervals and their
interrelation, and can be used for model selection.
Keywords: Radiobiological models, proton radiation therapy, carbon
ion radiation therapy, relative biological effectiveness, linear energy transfer,
bootstrap.
Sammanfattning
Det huvudsakliga målet med kurativ strålbehandling är att slå ut tumö-
ren utan att skada intilliggande frisk vävnad. Bestrålning med joner såsom
protoner och koljoner har blivit allt vanligare inom cancerbehandling. Joner
möjliggör en mer fokuserad dos till tumören och inducerar celldöd mer ef-
fektivt än traditionell strålterapi med fotoner (röntgenstrålning). Syftet med
denna avhandling är att utveckla och utvärdera matematiska modeller som
förutsäger den biologiska effekten av bestrålning, med fokus på proton- och
jonstrålning.
Två strålbiologiska modeller för joner har utvecklats. Den första utvid-
gar en cellöverlevnadsmodell, RCR-modellen, genom att ta hänsyn till den
linjära energiöverföringen (LET). Den andra estimerar den relativa biologis-
ka effektiviteten för protoner baserat på dos, LET, och celltyp. Den LET-
parametriserade RCR-modellen ger bra anpassning till experimentella cellö-
verlevnadsdata från bestrålning med kol- och heliumjoner. RBE-modellen
visar att sambandet mellan RBE och LET beror av celltyp, där celltypen de-
finieras av parametern α/β från den linjär-kvadratiska modellen för fotoner.
I ett separat arbete studerades effekten av en varierande RBE när behand-
lingsplaner jämförs. Med den föreslagna RBE-modellen erhölls lägre RBE
i tumören och högre RBE i intilliggande riskorgan än det allmänt antagna
värdet 1.1. Optimering utan hänsyn till RBE-variation kan ge en sämre pro-
tonplan än förväntat, om RBE skiljer sig från det antagna värdet 1.1, vilket
kan snedvrida jämförelser av planer.
Empiriskt härledda dos-responsrelationer för vävnadstoxicitet är osäkra
eftersom de utgår från ett begränsat antal patienter. En bootstrap-metod fö-
reslås för att uppskatta osäkerheten i klinisk utfallsdata som följd av varian-
sen i stickprovet och omvandla detta till en osäkerhet i dos-responsrelationer.
Metoden ger modellparameterskattningar med konfidensintervall och inbör-
des beroende, konfidensintervall for dos-responsrelationer, och stöd för mo-
dellval.
Nyckelord: Strålbiologiska modeller, protonterapi, koljonsterapi, relativ
biologisk effektivitet, linjär energiöverföring (LET), bootstrap.
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Introduction
In 1895, the physicist Wilhelm Conrad Röntgen discovered ’a new kind of ray’
that he called x-rays; the x representing the unknown. Within a year, radiation was
used to treat cancer and Röntgen was awarded the very first Nobel Prize in physics
in 1901 for his discovery. Over the years, radiation therapy has developed great-
ly. Some of the most important technological advances include the introduction of
linear accelerators in the 1960s that allowed for higher energies and thus deeper
tissue penetration compared to the Cobalt machines. With computed tomography
(CT), clinically available from the 1970s, three-dimensional images of the patient
anatomy were obtained. This technology has made it possible to better determine
the size, location, and density of tumors and normal tissue, and to align the beams
accordingly. The use of computers in e.g. treatment optimization and dose calcu-
lation has revolutionized radiation therapy. The invention of intensity modulated
radiation therapy (IMRT) (Brahme et al., 1982; Brahme, 1988) was an important
step in the direction of improving the delivered dose distribution to conform the
dose to the tumor. Another approach to focus the dose to the tumor has been to,
instead of x-rays, use protons and heavier ions. This was first realized by Robert
Wilson in 1946, and is described in his paper with the title Radiological use of
fast protons (Wilson et al., 1946). The first patient was treated with protons in
1954 in Berkeley, USA. Proton radiation therapy commenced in Europe in 1957 in
Uppsala, Sweden. In Berkeley, patients were treated with helium ion starting from
1975 (Saunders et al., 1985), and later also heavier ions such as neons (Castro et al.,
1982, 1994).
Today radiation therapy is one of the most common ways to treat cancer along
with surgery and chemotherapy. Often a combination of treatments is applied. Can-
cer is a leading cause of death in the world (WHO, 2013). It is a term for a group of
various diseases that involve uncontrolled cell division. Normal cells may turn can-
cerous after accumulating several mutations in genes that control cell proliferation
leading to a disruption in the normal balance between proliferation and cell death.
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The resulting uncontrolled cell division can lead to a mass of cells – a tumor. Ear-
ly in its development, when the tumor is generally well localized, and also when
regional spread has occurred or when the tumor is inseparable from vital organs or
tissues, radiation therapy may be indicated. About one in three people in Sweden
will suffer from cancer during the course of their life, and about half of the patients
are treated with radiation therapy (Cancerfonden, 2013).
The fundamental challenge in radiation therapy, as in all cancer treatment, is
to find the right balance between eradicating the cancer and avoiding unacceptable
injury to normal tissue. Most radiation therapy treatments today are given using
photons, but there is an increasing interest in protons and carbon ions as reflected
by the growing number of proton and carbon ion radiation therapy centers. These
particles allow for a more focused dose to the tumor and higher efficiency in cell
killing. The term ion will in this thesis mainly refer to protons (hydrogen ions) and
carbon ions.
Radiation physics
Ionizing radiation refers to radiation with energy high enough to overcome the
electron-binding energy in an atom or molecule. Every radiation type has its own
characteristic distribution of energy depositions. The distribution affects the induc-
tion of physical, chemical and biological changes. Two important physical quan-
tities in radiation therapy that affect the biological outcome are the absorbed dose
and the linear energy transfer (LET).
Depth dose distribution
The important quantity absorbed dose is defined as the expectation value of the
energy imparted by ionizing radiation to matter per unit mass at a point of inte-
rest (ICRU, 1980). It is expressed in units of Gray (Gy) where 1 Gy = 1 J/kg.
High energetic photons used in radiation therapy such as x-rays lose energy to
the traversed materia mainly by three processes: 1) photoelectric effect, in which
the photon interacts with a bound inner shell electron in an atom of the traversed
materia and transfers its total energy to the electron which is emitted; 2) Compton
scattering, in which the photon interacts with an outer orbital electron and transfers
part of its energy to the emitting electron, after which the photon is scattered with
reduced energy; and 3) pair production, in which the photon energy is converted
to the mass and kinetic energy of an electron-positron pair. The likelihood of each
of these processes depends on the energy of the photon and the atomic number
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Figure 1: Depth dose profiles for broad beams of 6 MV photons and 135-200 MeV
protons. By superpositioning several Bragg peaks of different energies, a spread-
out Bragg peak is produced. (Courtesy of Albin Fredriksson.)
of the target atom. The emitted electrons in the different processes lose energy
in turn by further ionization and excitation events. A typical photon depth dose
curve, the dose distribution on the central axis, in a patient shows a low surface
dose giving a so-called skin sparing effect. The dose is ”built-up” by secondary
electrons and increases with depth to a maximum, at a depth (a few millimeters
to a few centimeters) depending mainly on the beam energy, and then decreases
almost exponentially until the beam exit point (see Figure 1).
Except for very superficial tumors, it is not opportune to treat with a single
photon beam. The proximal dose in the normal tissue would be higher than the
dose delivered to the tumor, and the dose beyond the tumor would also be too high.
Instead multiple beams from several directions are combined.
High-energetic ions, on the other hand, interact with tissue mainly through
Coulomb interactions with the atomic electrons of the material. The energy loss
per unit path length of a particle, referred to as the stopping power, depends on
the electron density of the traversed medium, the atomic number of the ion, the
velocity of the ion, and the effective charge of the ion. Since the rate of energy
4 INTRODUCTION
transfer is inversely proportional to the square of the velocity of the ion, the energy
deposition is small at high velocities. As a consequence, the deposited dose is low
at small depths where the ions have their highest energy. As the ions slow down,
the dose increases with depth and forms a sharp maximum at the end of the range,
the Bragg peak. For protons, the fall-off in energy depositions beyond the Bragg
peak is sharp. With increasing atomic number of the ion, nuclear fragmentation
increases causing energy depositions beyond the Bragg peak forming a so called
fragmentation tail. Thus, for carbon ions some dose is deposited beyond the peak.
The height of the Bragg peak depends on the mass of the ions, and the range of an
ion, and thus the location of the Bragg peak, is determined by the initial energy.
At the depth of the Bragg peak there is a spread of energies due to fluctuations
between ions in the number of collisions and transferred energies. This is known
as range straggling or energy-loss straggling. In summary, a low dose is obtained
at the entrance, the dose peaks at the end of the track, and very little dose is depo-
sited behind the peak. This feature of ions is utilized in radiation therapy to obtain
a more focused dose to deep-seated tumors than would be possible with photons,
while lowering the dose to the normal tissue.
The width of a Bragg peak is too small to cover an entire tumor. By superposi-
tioning several Bragg peaks of different energies a so called spread-out Bragg peak
is obtained, shown in Figure 1.
Linear energy transfer
In ion irradiation, not only the amount of energy deposited in a volume (the dose) is
of importance but also how the energy depositions are distributed. The spatial dis-
tribution of energy depositions influences the effectiveness in producing radiation-
induced changes. One way of characterizing this local energy spectrum is by the
linear energy transfer, LET. LET is closely related to the collision stopping power
and is a measure of the average energy locally imparted to the material by a charged
particle per unit length of the particle track (ICRU, 1970)
L∆ =
(
dE
dl
)
∆
(1)
where dE is the mean energy loss due to collisions with energy transfers less than a
cut-off value ∆, and dl is the distance traversed by the particle. Whereas stopping
power focuses on the energy loss of the particle, LET focuses on the energy ab-
sorbed by the material. The cut-off value ∆ is an energy limit to restrict to energy
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losses occurring ”locally” by excluding secondary electrons with energies excee-
ding ∆. In the unrestricted LET, L∞, all possible energy transfers are included.
LET is useful for defining the quality of ionizing radiation. A distinction between
low- and high-LET radiation is often made. Low-LET radiation, or sparsely ioni-
zing radiation, such as electrons, experience many interactions with material and
the ionizations produced are distributed over a relatively long path resulting in a
low ionization density. 60Co γ-rays or x-rays are usually also referred to as low-
LET radiation, although the definition of LET is limited to charged particles, since
the electrons generated from photon interactions have generally low LET. In con-
trast, high-LET radiation, such as carbon ions, deposit a large amount of energy
in a small distance and produce in that way more clustered, and thereby more se-
vere, DNA damage. Protons may produce high LET in the Bragg peak but belong
generally to radiation of low LET.
In most experimental situations, there is a distribution of LET values. An ave-
rage LET at every position can be calculated and the two most common measures
are the dose averaged LET and the track (or fluence) averaged LET. A dose avera-
ged LET can be calculated by weighting the LET contribution of each proton by
the dose it deposits, and a track averaged LET is obtained by weighting the LET
by the number of particles, i.e. it is the arithmetic mean LET.
LET is one of the descriptors of the radiation quality and has been found to cor-
relate with the relative biological effectiveness. Alternative measures of radiation
quality might be the number of ionizations per path length, or the microdosimetric
quantity dose-mean linear energy. A measure that more uniquely describes the ra-
diation quality would be beneficial.
Radiation biology
Radiation biology, or radiobiology, is the study of the effects of radiation on living
systems. Absorbed radiation dose is an important quantity when predicting the bi-
ological effect. However, there are many factors that affect the biological response
to a given dose: the inherent radiosensitivity of the biological system studied, the
degree of oxygenation, the dose distribution within the irradiated volume, the way
dose is fractionated, e.g. dose per fraction, the time between fractions, overall tre-
atment time, etc. Moreover, for ions the LET has to be considered, as described
above.
6 INTRODUCTION
DNA damage
The DNA (deoxyribonucleic acid) in the cell nucleus is considered to be the most
important target for radiobiological effects. DNA has a double helix structure with
two polynucleotide strands held together by hydrogen bonds between the bases of
the nucleotides. The double-ringed nucleobases adenine (A) and guanine (G) pair
with the single-ringed thymine (T) and cytosine (C), respectively. The double helix
interacts with small protein complexes called histones and is arranged in a compact
structure called chromatin. The structure of chromatin depends on the stage of the
cell cycle: during replication and transcription the chromatin is loosely structured
whereas during cell division it is tightly packed.
Radiation may cause damage to the DNA, e.g. in the form of breaks on the
strands, either directly by ionizing the DNA or indirectly by forming free radicals
that damage the DNA. However, DNA damage is not always lethal to the cell.
Single strand breaks rarely cause cell death in normal cells since they are easily
repaired by the repair system of the cell using the opposite strand as a template.
Double strand breaks, breaks close to each other on both of the strands, are mo-
re difficult to repair. Cells have two main processes to repair these latter lesions:
homologous recombination and non-homologous end joining (Jackson, 2002). In
homologous recombination, the sister chromatid or the homologous chromosome
is used as a template and the information is copied. In non-homologous end jo-
ining the broken strands are simply rejoined and this process is therefore more
error-prone. An even more severe damage is multiple strand breaks close to each
other, sometimes called clustered DNA damage.
In the repair process, DNA breaks may fail to rejoin correctly and form chro-
mosome aberrations. Serious chromosome changes hinder correct cell division and
lead to mitotic death.
High-LET radiation is believed to cause damage that is more difficult to repair
compared to low-LET radiation due to the dense ionization pattern which causes
multiple strand breaks close in space to a higher degree (Goodhead, 1994; Karlsson
and Stenerlöw, 2004). Consequently, the ability of high-LET radiation to cause
non-repairable DNA damage is less dependent on alterations such as mutations
affecting the cell’s repair capacity, cell cycle phase, and environmental conditions
such as oxygen pressure.
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Cellular response to radiation
One way of measuring the biological effect following irradiation is by the cell
survival fraction. The definition of cell survival differs with the context. For pro-
liferating cells, the term clonogenic cell survival is often used and refers to cells
that have retained their reproductive capacity i.e. cells still capable of undergoing
cell division. Cells that are metabolically functioning but not able to divide are not
considered survivors with this definition. For most cell types, the dominant mecha-
nism of cell death is mitotic death, i.e. death while attempting to divide (Hall and
Giaccia, 2006). Another important mechanism for certain cell types is apoptosis,
programmed cell death, where the demolition of the cell is more controlled.
A cell survival curve describes the relationship between the absorbed dose and
the fraction of cells that survive (see Figure 2). The survival fraction is obtained
in vitro as the ratio of the plating efficiency of treated cells to that of untreated
control cells, where the plating efficiency is the percentage of seeded cells that
grow into colonies. Conventionally, the survival fraction is plotted on a log-linear
scale with dose on the linear x-axis. The shape of clonogenic cell survival curves
as a function of dose is influenced by the type of radiation. For low-LET radiation,
the survival curve on a log-linear scale is characterized by a curvature or, as it is
commonly called, a shoulder region over the low dose range. For high doses, the
curve tends to be more linear, indicating an exponential decrease in cell survival.
Historically, two explanations for the curvature have been put forward: interactions
of lesions lead to a bend towards lower survival rates; or repair of DNA lesions
results in higher survival rates at low to intermediate doses. These theories need
not to be mutually exclusive but may be two aspects of the same phenomenon. At
low doses the probability of damaging events close to each other may be low giving
mostly easily repairable DNA damage, while with increasing dose, the probability
of interacting, clustered, damage increases resulting in more severe damage.
Mammalian cells vary considerably in their response to radiation with resistant
cell lines showing a large shoulder and sensitive cell lines demonstrating a rapid
decrease in the number of colonies formed with increasing dose (Hall and Giac-
cia, 2006). Cell types prone to apoptotic cell death are more sensitive to radiation
than cells dominated by mitotic death, and fast proliferating cells tend to be mo-
re sensitive than slowly proliferating cells. Tumor cells generally divide at a high
rate and often have malfunctioning cell cycle arrests and repair systems leading to
accumulated mutations and damage following irradiation.
In contrast to low-LET radiation, the response following ion radiation shows
less dependence on cell type and produces a more straight line in a log-linear sca-
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le. Generally, the higher the LET of a radiation the steeper the slope, the more
shifted towards lower survival levels, and the smaller the shoulder. An explanation
is that high-LET radiation produces more severe damage due to higher probabili-
ty of damaging events close to each other. However, there is an optimal LET for
cell inactivation after which there is a reduced effectiveness in cell inactivation per
unit dose with the effect that the slope of the survival curve decrease again. This
phenomenon is sometimes called overkill effect.
The biological effectiveness of inducing cell death following ion irradiation is
often described in relation to that of photons through the concept of relative biolo-
gical effectiveness (RBE). The higher the RBE the more effective is the radiation
type (see further at page 28).
Organ and tumor response to radiation
Clinical radiation biology often focuses on the relationship between the absorbed
dose and resulting response, and on factors influencing this relation. The response
in often described as a probability of a specific outcome for the normal tissue or
the tumor, typically showing a sigmoid dose-response curve.
Tissues can be classified as serial or parallel, or somewhere in between, based
on how their functional subunits are organized. Serial tissues, such as the spinal
cord and brain stem, may lose their function even if only a small proportion is se-
verely damaged. Parallel tissues, such as lung and liver, can function even when
substantial parts are damaged. Tumors are always assumed to have a parallel fun-
ction since all clonogenic cells need to be eradicated in order to achieve tumor
control.
The response of normal tissues can also be divided into early and late occurring
damage, reflecting the time of occurrence of side effects. Rapidly dividing tissues
such as skin, bone-marrow, and intestinal epithelium respond early to radiation.
Late-responding tissues are for example spinal cord, lung, and kidney.
Dose fractionation
Dose fractionation is the practice of dividing the therapeutic dose into smaller do-
ses delivered over a period of time. It is a key determinant of the therapeutic re-
sponse. The rational of fractionation is that normal tissues are well-organized and
have well-functioning repair systems and may therefore repair radiation-induced
damage to some extent between the fractions, whereas tumors are more chaotic in
their structure and generally less capable of repair. Another reason is that the fast
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Figure 2: Illustration of cell survival curves obtained following photon irradiation
(blue curves) and ion irradiation (black curves). The dashed lines show the survival
fraction as a function of single dose, and demonstrate the higher effectiveness of
ions over photons. The solid lines illustrate the dose fractionation effect and show
the survival fraction after repeated 2 Gy-fractions with complete repair in between.
and poorly organized tumor growth often leads to poor vascular networks resulting
in insufficient oxygen levels. Poor oxygenation results in radioresistant cells (Vau-
pel and Mayer, 2007). After the delivery of dose fractions, the oxygen supply may
be improved by hypoxic cells turning oxic due to eradication of the more oxic,
radiosensitive, tumor cells or through the reopening of previously closed blood
vessels (Toma-Dasu and Dasu, 2013). The main biological processes that affect
the fractionation effect are summarized by the five R’s of radiobiology:
1. Repair: Repair is one of the primary reasons for fractionation. The smaller
dose fractions separated in time allow normal tissue to recover, and normal
tissue with intact repair capacity generally has a better ability to repair da-
mage than tumors.
2. Redistribution: Cells in some phases of the cell cycle (M and G2) are more
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radiosensitive than in other (S). Dose delivery over time allows for redistri-
bution so that tumor cells in a resistant phase continue to cycle into a more
sensitive phase.
3. Reoxygenation: Tumor hypoxia is a condition where tumor cells are deprived
of oxygen making them more radioresistant than well oxygenated cells. The
oxygenation status may change during treatment and dividing the dose may
allow more tumor cells to be eradicated.
4. Repopulation: A prolonged treatment allows normal cells to proliferate which
is beneficial. However, also tumor cells proliferate and, especially for fast-
growing tumors, a too long treatment time may lead to tumor regrowth.
5. Radiosensitivity: There is also an intrinsic radiosensitivity depending on cell
type.
Late-responding tissues are more sensitive to changes in fractionation patterns
than early-responding tissues. The difference between these tissues in their respon-
se to changes in fractionation could be understood from the differences in their
dose-response relations. The cell survival curve for late-responding tissues, with
its more curved shape compared to early-responding tissues after photon irradi-
ation, show more sparing when the dose is fractionated. Fewer and larger dose
fractions result in more severe late effects even when the total dose is adjusted to
produce equal early effects (Hall, 2006). The response following high-LET radia-
tion, with generally straighter cell survival curves, is consequently less affected by
fractionation. An illustration of the fractionation effect is shown in Figure 2.
Commonly, around 1.8-2.0 Gy are given per day, five days a week and the
treatment takes around 5-7 weeks. For certain tumors, unconventional fractionation
schedules have been explored with the hope of increasing the therapeutic ratio.
With hyperfractionation, many smaller dose fractions are delivered for example
twice a day, whereas in hypofractionation fewer and larger dose fractions are used.
Radiation therapy
Radiation therapy is the use of ionizing radiation for medical treatment, most often
of cancer. The ability to ionize atoms and/or molecular structures in the cells, and
in that way cause cell death, is utilized. It is given both with the intention to cure the
patient and for palliative care, where the aim is to reduce pain or other symptoms.
In external beam radiation therapy, which is most commonly used and considered
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in this thesis, the patient is exposed to an externally generated beam directed to-
wards the tumor. In internal radiation therapy (brachytherapy), radioactive sources
are placed directly at the site of treatment. Some of the advantages of radiation the-
rapy, compared to surgery and chemotherapy, are that it is non-invasive and carries
few systemic side effects. Therefore, it may be offered to patients suffering from
e.g. cardiovascular disease, poor lung function, locally advanced cancer or that are
otherwise unfit for surgery; or to patients with e.g. dysfunction of the liver, kidney,
bone-marrow or otherwise unfit for chemotherapy.
Photon therapy
Photon radiation (x-rays and γ-rays) is the most common modality of radiation. It
is widely used and available at most treatment centers. Photons in radiation therapy
are typically produced by accelerating electrons in a linear accelerator and colli-
ding them onto a high atomic number target. The resulting high-energetic photons
produced are filtered to obtain a uniform intensity field and shaped by a multileaf
collimator (MLC). MLC is a beam shaping device consisting of two rows of pair-
wise opposing leaves of high atomic number material used to create patient-specific
field apertures. The accelerator, the beam transport system with bending magnets,
and the field-shaping devices are all mounted on a gantry that can rotate around the
patient. By rotating the gantry and changing the leaf positions in the MLC, multiple
beams from different angles, each shaped as the corresponding tumor projection,
Figure 3: Intensity modulated radiation therapy for a head and neck case. For each
beam direction, multiple MLC apertures together yield a fluence modulated field.
Combining the fluences from all beam directions together gives the dose distribu-
tion in the patient. (Courtesy of Albin Fredriksson and Rasmus Bokrantz.)
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give overlapping fields that together conform the tumor volume, a technique called
three-dimensional conformal radiation therapy (3DCRT). Thereby a higher dose is
delivered to the tumor than to the surrounding normal tissue. In intensity modulated
radiation therapy (IMRT), this technique is further improved with the introduction
of non-uniform beam fluence profiles. From each beam direction, multiple subse-
quent apertures together form a field with modulated fluence (see Figure 3). The
concept of IMRT was first proposed by Brahme et al. (1982) and Brahme (1988)
and is now widely used. This technique yields high conformity in the irradiation
of the tumor while avoiding high doses to normal tissue. Instead, larger volumes
of normal tissue are typically exposed to low doses compared to 3DCRT, and so-
me concerns about secondary cancer induction in long-term survivors have been
raised (Hall, 2006). For reviews of IMRT, see e.g. (Ahnesjö et al., 2006; Bortfeld,
2006)
Proton and carbon ion therapy
The main advantages of protons and carbon ions over photons in radiation therapy
are: 1) The low dose in the entrance region that slowly increases to near the end
of the beam range where a steep increase in dose depositions occur, the Bragg
peak, after which the dose sharply drops. This allows for sparing normal tissues
surrounding the tumor, and fewer beams are required. 2) The increased biological
effectiveness in cell killing at the end of the particle range. The high RBE of carbon
ions may be advantageous for radioresitant tumors. Finally, 3) the range of the
particles can be controlled by changing their initial energy and thereby the location
of the increased dose and effectiveness can be adjusted. However, the range is
highly dependent on the stopping power of the traversed medium, which makes
protons and carbon ions more sensitive to geometric uncertainties compared to
photons. Another disadvantage is the higher cost of setting up the treatment centers.
The beneficial properties of ions can be utilized for improving the probability
of local tumor control by delivering higher doses, or for reducing radiation-induced
side effects by limiting the dose to normal tissue, or a combination of them. The
decreased volume of normal tissue exposed to low doses compared to IMRT may
also reduce the risk of radiation-induced secondary cancer. This is particularly im-
portant for young patients. Moreover, treatment of radioresitant tumors such as
melanoma and sarcomas and hypoxic tumors, which are not efficiently cured by
conventional radiation therapy, may benefit from the high RBE of carbon ions. For
reviews on radiobiological aspects of ion therapy see e.g. (Brahme, 2004; Schulz-
Ertner et al., 2006; Jones, 2008; Fokas et al., 2009; Allen et al., 2011).
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In ion therapy, a narrow beam is extracted from a particle accelerator. To co-
ver a tumor volume, two main approaches exist: In passive scattering, the beam is
broadened laterally by scattering foils and spread out in depth by range modula-
ting devices. The beam can be further shaped laterally by patient-specific apertures
and in depth by modulating the distal edge of the beam with patient-specific range
compensators. The second technique, pencil beam scanning which is considered
in this thesis, the narrow beam is magnetically deflected to scan the beam over the
target volume laterally and spread out in depth by changing its energy. A more
conform dose distribution to the tumor compared to passive scattering can general-
ly be achieved without patient-specific hardware. More importantly, pencil beam
scanning enables intensity modulated proton therapy (IMPT). By varying the time
of the pencil beam at each position, the dose distribution can be modulated in three
dimensions even from a single beam direction.
Around 35 proton facilities are treating patients today and over 90.000 pati-
ents have been treated (PTCOG, 2013). Carbon ions have been used for treatment
for a shorter period of time, and six facilities are operating today, three in Japan
and one in each of Germany, Italy and China, with over 10.000 patients treated in
total (PTCOG, 2013).
Treatment planning
For each patient, an individual treatment plan is made. The patient’s internal ana-
tomy is imaged, most often by computed tomography (CT), with the patient im-
mobilized in the position to be used during irradiation. The CT produces cross-
sectional x-ray images (or ’slices’) that are processed into a three-dimensional (3D)
image. Other medical imaging techniques include magnetic resonance (MR) ima-
ging and positron emission tomography (PET).
From the images, the different regions of interest (ROIs) are determined and
contoured. The volume including the macroscopic disease, visible from the image,
is called the gross tumor volume (GTV). To account for the possible microscopic
regional spread of the tumor, a so called clinical target volume (CTV) is contou-
red, which is an extension of the GTV. The CTV can be further expanded into a
planning target volume (PTV) to account for uncertainties arising from e.g. pa-
tient positioning errors and organ motion. Organs at risk (OAR), i.e. organs that
may be significantly affected by the radiation, are also contoured. The quantitative
physical tissue information obtained from CT images is used also for computing
the dose distribution after conversion from Hounsfield units into mass attenuation
coefficients.
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The treatment planning goals are usually stated in terms of a desired dose distri-
bution. The desired dose to the tumor, generally referred to as the prescribed dose,
and the constraints for the irradiation of normal tissue can be stated for example in
the following way:
• deliver the prescription dose to at least 95% of the tumor volume
• deliver no less than 95% and no more than 107% of the prescription dose
across the tumor volume
• the maximum dose to the ROI may not exceed x Gy
• no more than v% of the ROI volume may receive x Gy (Dv% ≤ x)
Dose-volume indices can be represented by a cumulative dose-volume histo-
gram (DVH). The DVH is a cumulative frequency distribution that summarizes a
3D dose distribution in a given volume into a 2D graph. It shows the fraction of the
ROI that receives a dose equal to or greater than a given dose level (see Figure 4).
Also biological goals can be stated:
• The probability to achieve local tumor control should be at least p%
• The probability to obtain a specified complication should not exceed p%
• The equivalent uniform dose should be x Gy or less
Based on the goals, optimization functions, and possibly constraints, are cho-
sen. Typically, optimization functions penalize deviations from the desired dose
criterion in a ROI, and are to be minimized. Several functions can be combined
into a single objective function using weights to reflect their relative importance.
Biologically-based function can also be optimized such as tumor control probabili-
ty (TCP) and normal tissue complication probability (NTCP). Numerical optimiza-
tion techniques are usually used that perform an iterative search through the space
of treatment variables to obtain an optimal solution.
The resulting plan needs to be evaluated. The risk of complications (measured
directly or indirectly) for each OAR should be acceptably low and the probability
of local tumor control should be as high as possible. Often some changes are nee-
ded and new optimizations are performed before a satisfying plan is obtained. This
iterative manual process of finding a satisfactory trade-off between tumor coverage
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Figure 4: Dose volume histograms and dose volume indices for a tumor volume
(red) and an organ (blue). 98% of the tumor volume receive 58.7 Gy or more, and
25% of the organ volume receives 40 Gy or more.
and sparing of different normal tissues can be avoided with multicriteria optimi-
zation (Monz et al., 2008; Bokrantz, 2013). Often multiple plans are obtained and
compared to determine the best plan.
The difference in planning photon beam therapy and proton and light ion beam
therapy stems from differences in physical properties and biological effective-
ness (Goitein, 2008). The ability of ions to closely conform the tumor makes them
less forgiving if the tumor is somewhat missed. The finite range of ions is strongly
affected by the density of the traversed tissue and makes them therefore more sensi-
tive to uncertainties. It is therefore more important to position the patient correctly,
and to select ’good’ beam directions to avoid beams passing complex inhomoge-
neities and stopping just before critical structures, if possible. The use of a planning
target volume as in photon therapy is less applicable in therapy with intensity mo-
dulated charged particles since the PTV generally does not account for the pertur-
bed dose distribution that may arise from changes in densities due to setup errors or
organ motion. Optimization methods that account for geometric uncertainties have
been developed (Unkelbach et al., 2009; Fredriksson, 2013).
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The biological effect of a given dose distribution also differs between photons
and ions. For ions, the RBE is used to weight the physical dose to reflect the bi-
ological impact. For carbon ions, the RBE can be high and varies considerably
across the treatment plan (Kanai et al., 1997; Krämer and Scholz, 2000). Different
approaches to account for the RBE of carbon ions are used at different treatment
facilities, but they all include a mathematical model for biological effect estima-
tion (Kanai et al., 1997, 1999; Krämer and Scholz, 2000; Combs et al., 2010). For
protons, a constant RBE equal to 1.1 is usually assumed in the clinics, although it
has been recognized that this assumption is a simplification (ICRU, 2007).
Designing good treatment plans is a complex task. Many factors must be con-
sidered and balanced to reach a satisfactory plan. To obtain an optimal treatment
plan, it is necessary to know what factors influence the outcome and in what way.
Mathematical radiobiological models aim to describe the relation between physical
quantities of radiation and biological response.
Aim of the thesis
The aim of this thesis is to develop and evaluate mathematical models for biolo-
gical effect estimation, with the focus on proton and light ion irradiation. Paper I
proposes an extension of the repairable-conditionally repairable damage model to
account for the local energy deposition spectrum, as characterized by the LET, for
cell survival under light ion irradiation. Paper II proposes a mathematical model
to predict the relative biological effectiveness of protons, accounting for cell type,
LET, and dose. Paper III evaluates the impact of the RBE variation predicted by the
model developed in Paper II in a realistic treatment planning setting, with compari-
son to the common assumption of a constant RBE equal to 1.1. Paper IV proposes
a statistical bootstrap analysis that assesses the uncertainty in clinical outcome data
and estimated dose-response relations, due to sampling variability (limited amount
of experimental data); the framework is evaluated on photon dose-response data,
but is applicable to any model of biological effect estimated from data.
Modeling of radiobiological
effects
Mathematical radiobiological models are used for a variety of purposes: to descri-
be the relation between physical quantities of radiation and biological response,
to interpolate between known outcomes and to extrapolate beyond what has been
studied, to suggest hypotheses to be tested experimentally, to estimate the possible
gain of a new treatment strategy, to compare treatment plans, to assist in com-
bining treatment modalities, to re-plan after a non-scheduled treatment interrup-
tion, to compensate for earlier delivered over- or underdosage, generally to assist
in decision-making, and more. It is not possible to experimentally test all com-
binations of irradiation conditions of interest. With mathematical models, what-if
analyses are easily made to explore the impact of changes in the input assump-
tions. Radiobiological models are also used to convert the absorbed dose to clini-
cally more relevant quantities such as biologically equivalent dose, tumor control
probability and normal tissue complication probability. In ion radiation therapy,
radiobiological models are used to estimate the relative biological effectiveness.
Cell survival models
A cell survival curve describes the relationship between the absorbed dose and the
fraction of surviving cells. Cell survival models aim to describe this curve, and form
the basis for many dose-response models. The latter describe the probability of a
specific biological response at a given dose. Three cell survival models are descri-
bed here: the linear, the linear-quadratic (LQ), and the repairable-conditionally re-
pairable damage (RCR) model. The linear model is the simplest, the LQ model is
the most widely used, and the RCR model is a newly developed model with some
advantageous properties. Other models include those described by Tobias (1985);
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Curtis (1986) and Sontag (1997) and models based on target theory first described
by Lea (1946).
The linear cell survival model
The clonogenic cell survival as a function of dose is in a first approximation an
exponential process. In the simple linear cell survival model it is assumed that a
single ”hit” or ”damaging event” on a critical target in the cell leads to cell death.
The expression for expected survival fraction is
SL(D) =
N(D)
N0
= e
− D
D0 (2)
where N(D) denotes the number of cells surviving a dose D, N0 is the initial
number of cells, and D0 is the dose giving one hit per target on average, which
reduces the survival fraction by a factor 0.37 (e−1). The model is also called the
single-hit single-target model.
The linear-quadratic cell survival model
The fraction of surviving cells as a function of dose is usually not an entirely expo-
nential process as assumed by the linear cell survival model, but exhibits a curva-
ture. The linear-quadratic (LQ) model (Lea and Catcheside, 1942; Sinclair, 1966;
Kellerer and Rossi, 1978; Chadwick and Leenhouts, 1973; Barendsen, 1982) can
handle this type of response. This is a well-established and widely used model. For
a single dose (one dose fraction) the model is expressed as:
SLQ(d) = e
−αd−βd2 (3)
where α and β are the parameters of the model. α is associated with the initial slope
and β with the curvature. The α/β ratio describes the fractionation sensitivity of
a tissue and the inherent sensitivity of a cell type. As a general rule of thumb,
late-responding tissues have low α/β values (around 3 Gy) while early-responding
normal tissue and most tumors have a larger α/β value (around 10 Gy). There are
exceptions such as prostate tumors with biological properties more like those of
slowly proliferating late-responding tissues (Brenner and Hall, 1999) and exhibit a
low α/β ratio around 1.5 Gy (Dasu and Toma-Dasu, 2012; Fowler et al., 2013). A
small α/β value indicates that large fractional doses are not well tolerated.
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The total survival fraction after n dose fractions is obtained as
SLQ(D) =
n∏
k=1
SLQ(dk) =
n∏
k=1
e−αdk−βd
2
k
= exp
(
n∑
k=1
(−αdk − βd2k)
)
= exp
(
n∑
k=1
−αdk
(
1 +
dk
α/β
))
(4)
where D denotes the total dose, and dk is the dose of the kth fraction. When the
fractional doses are equal this expression simplifies to
SLQ(D) = (SLQ(d))
n = e−αnd−βnd
2
= e
−αD(1+ d
α/β
)
. (5)
In its simplest form, it is assumed that full repair of sub-lethal damage occurs
between each dose fraction, and that no repopulation occurs. The LQ model can be
reformulated to account for incomplete repair due to dose fractions close in time,
and to account for the effect that cells may start to divide at a higher rate after so-
me time following irradiation (Dale and Jones, 2007). Furthermore, the inducible
repair model (Joiner and Johns, 1988) is a modified LQ model to handle low-dose
hypersensitivity, the phenomenon observed experimentally of high radiation sensi-
tivity to doses below around 0.5 Gy (Joiner et al., 2001).
A drawback with this model is the constant curvature which is not consistent
with experimental observations which indicate that the survival curve becomes mo-
re or less linear (in a log-linear scale) at high doses. The model is therefore modified
in the local effect model (LEM), where the LQ model is a part, used clinically in
the carbon ion treatment in Heidelberg (Scholz et al., 1997; Elsässer and Scholz,
2007; Elsässer et al., 2008, 2010). In LEM, the curve is simply extrapolated by a
straight line at doses higher than at threshold dose dt:
SLQ′(d) =
{
e−αd−βd2 if d ≤ dt
e−αd−βd2−(α+2β)(d−dt) if d > dt
(6)
The LQ model may also be inappropriate for treatments with high doses per
fractions used in stereotactic radiation therapy and in hypofractionation (Kirkpa-
trick et al., 2009), and for ions showing a cell survival curve with a small shoulder
that transform into an exponential curve already at low doses.
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The repairable- conditionally repairable damage model
The repairable- conditionally repairable damage (RCR) model (Lind et al., 2003)
is a radiobiological model that can describe cell survival for a wide range of doses
accounting for low-dose hypersensitivity, the shoulder region, and a quasi-linear
survival curve for high doses. It separates the probability of inducing damage and
the probability of cellular repair, enabling studies of these effects individually. The
RCR model assumes that a cell can survive either by not receiving any damage or
by correctly repairing the acquired damage. The cell survival fraction as a function
of dose is approximated by
SRCR(D) = e
−aD + bDe−cD (7)
where D denotes the dose, and a, b, and c are the parameters of the model. The
first term, exp (−aD), represents the fraction of cells not being damaged, and the
second term, bD exp(−cD), is the fraction of cells that have been damaged and
subsequently repaired.
In Paper I, we extended the RCR model with a parameterization by LET to
provide a radiobiological model for ions that accounts for both dose and LET. The
LET dependence was incorporated in the RCR model by expressing its parameters
a, b, and c as functions of LET (L) instead of free parameters. In that way, the mo-
del can directly estimate the survival fraction for any dose and LET combination.
The survival fraction expressed with the LET-parameterized RCR model is
SRCR(D) = e
−a(L)D + b(L)De−c(L)D (8)
where
a(L) = a0e
−
(
L
La
)2
b(L) = b0e
− L
Lb
c(L) =
c0
L/Lc
(
1− e− LLc
(
1 +
L
Lc
))
(9)
With these expressions, the fraction of damaged cells as a function of LET,
fdamage(L) = 1− e−a(L)D, (10)
decreases rapidly at high LETs for a constant dose level due to damage clustering,
and the normalized fraction of repaired cell,
frepair(L) =
b(L)De−c(L)D
1− e−a(L)D , (11)
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shows a decrease already at low LETs.
The model predicts a cell survival curve with negative slope that increases with
increasing LET and exhibits a shoulder that decreases with increasing LET. More-
over, it handles the reduced effectiveness in cell inactivation for LETs higher than
the optimal LET giving decreasing slopes again but still with no or greatly reduced
shoulders. This overkill effect could be explained by a trade-off between the se-
verity and number of lethal events so that even more severe damage in fewer sites
becomes less effective.
By expressing the parameters as functions of LET instead of as free parameters,
and by fitting the cell survival curves of all LETs simultaneously instead of for each
LET, a somewhat less accurate fit to the experimental data for a given cell line is
obtained. The benefits include the possibility to estimate cell survival also for dose
and LET combinations for which we have no experimental data available, and the
reduced risk of overfitting to available experimental data.
Tumor control and normal tissue complication probability
models
In clinical radiation biology, the response of a biological system following irradi-
ation is often expressed as a probability of response. The normal tissue complica-
tion probability (NTCP) and the tumor control probability (TCP) depend on a large
number of factors. Here we consider mainly dose and volume effects.
Dose-response models
A dose-response model describes the response probability as a function of dose.
Usually a sigmoid relation is assumed, most often characterized by its position
and the steepness of its slope. The position of the curve is usually quantified by
the dose required to obtain a certain probability of response such as 37% (D37) or
50% (D50). The often preferred description of the slope is the so called normalized
dose-response gradient where the dose-response gradient is steepest, γ (Brahme,
1984). It describes the change in response probability for a given relative increase
in absorbed dose.
Poisson distribution based models
Assume that there are N0 clonogenic tumor cells or functional subunits to begin
with, all with the same probability of survival at a given dose, S(D), and that the
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survival of each cell is independent of the survival of other cells. Then the number
of surviving cells X follows the binomial distribution X ∼ Bin(N0, S(D)).
The typical tumor contains a large number of clonogenic tumor cells, and ef-
fective irradiation requires that the probability of survival for each individual cell
is low. Under such circumstances, the Poisson distribution is a good approxima-
tion of the binomial distribution. The Poisson distribution is a discrete probability
distribution for random variables that denotes the number of discrete events in a
given interval. The probability mass function of a discrete stochastic variable X
that follows a Poisson distribution is given by
P (X = k | λ) = λ
ke−λ
k!
(12)
where k is the actual number of events and λ is the expected value.
In radiation therapy one important issue is how much dose is required to inac-
tivate the tumor, and it is usually assumed that all clonogenic tumor cells have to
be eradicated to control the tumor. In other words, the model seeks to estimate the
probability to eradicate all tumor cells (k = 0) given that the expected number of
surviving cells λ depends on the dose. The expected number of surviving cells can
be estimated from the initial number of cells N0 and the fraction of surviving cells
(probability of survival of each cell) S. From this, the probability of no surviving
cells can be expressed as
P (X = 0 | D) = e−λ(D) = e−N0S(D). (13)
The fraction of surviving cells can be obtained from a cell survival model, such
as the linear cell survival model (2), the LQ model (5) or the RCR model (7). Using
the linear cell survival model we obtain the following expression for the probability
of response as a function of dose
PL(X = 0 | D) = e−N0SL(D) = e−N0exp
(
− D
D0
)
(14)
This model can be expressed also by the clinically important parameters D50
and γ. Via the definition of γ (Brahme, 1984), the following relation with the initial
number of cells is obtained:
γ ≡ DmaxdP
dD
=
lnN0
e
. (15)
By inserting the dose giving a 0.5 probability for the response (D50) we obtain
D50 = D0 (eγ − ln (ln2)) . (16)
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The linear dose-response model can thus be expressed as
PL(X = 0 | D) = e−exp
(
eγ− D
D50
(eγ−ln(ln2))
)
. (17)
If instead the dose-response model is based on the LQ model, the following
expression is obtained:
PLQ(X = 0 | D) = e−N0SLQ(D) = e−N0exp
(
−αD
(
1+ d
α/β
))
=
= e
−exp
(
eγ−αD
(
1+ d
α/β
))
(18)
The parameter D50 can be included in the LQ model by assuming PLQ(D)
= PL(D) for a given fractional dose dref for which D50 and γ were determined,
usually 2 Gy, which gives (Lind et al., 1999):
α =
eγ − ln(ln2)
D50
(
1 + drefα/β
) (19)
Using this expression for the parameterα, the LQ dose-response model,PLQ(D),
is equivalent to the linear dose-response model using the equivalent dose (EQD, see
page 27) PL(EQD).
In practice, γ and D50 are not derived from (15) and (16), but treated as free
parameters and estimated with for example maximum likelihood to achieve the
best possible fit to the dose-response data at hand. In a similar fashion, the models
described above can be fitted to experimental data for normal tissue complication,
as in Paper IV for the dose-response relations of myelopathy (spinal cord) and
pneumonitis (lung).
Normal distribution based model
The Lyman model (Lyman, 1985) is based on the cumulative distribution function
of the normal distribution:
PLyman(D) =
1√
2pi
∫ t
−∞
e
−x2
2 dx =
1
2
(
1− erf
(
t√
2
))
(20)
with the upper limit t defined as
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t =
D −D50
mD50
where m denotes the slope.
Paper IV compared the Lyman model (20) and the Poisson-based linear dose-
response model (17) in terms of estimated parameters and the fit to clinical outcome
data.
Dose-volume response models
Different parts of an organ and, to a lesser extent, a tumor may be irradiated with
different doses. The probability of a given response depends on the distribution
of the dose within each volume. Organs also exhibit complex functional relations
between different compartments which means that the function of an organ may be
dependent of how large fraction of it has been irradiated. In this context the publi-
cation by Withers et al. (1988) has been important where they assume that normal
tissue behavior depends on its architecture, stated as being serial or parallel, as
described above. In a completely serial tissue, the inactivation of one functional
subunit is sufficient to cause the endpoint considered. For such tissues the proba-
bility of response is largely determined by the maximum dose. A parallel tissue
may preserve its function as long as a critical fraction of its volume is functioning.
For this type of tissue, the mean dose is an important measure for determining the
outcome probability.
In treatment planning, the patient geometry is discretized into small volume
elements called voxels. In calculating the response one assumes that these volumes
are small enough so that the dose is uniform within each one. All voxels are usu-
ally assumed to have the same radiosensitivity so that they respond with the same
probability to a specific dose. It is of course possible to designate a different radio-
sensitivity to for example a known hypoxic region within a tumor. Different voxels
are also considered independent. However, there have been observations that cells
communicate by intercellular signaling so that the response of cells do depend on
other cells, the so-called bystander effect (Prise and O’Sullivan, 2009).
The tumor control probability denotes the probability that the number of clo-
nogenic tumor cells capable of cell division is zero after the last dose fraction. The
TCP can be formulated as the product of the probabilities of cell death of all voxels
M as:
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TCP (D) =
M∏
i=1
(P (Di)) (21)
whereDi is the total dose to voxel i. A Poisson-based (13) or a binomial-based
dose-response expression can for example be used for P (Di). If a single voxel
receives no dose there is no change of eradicating all tumor cells in that voxel,
and the model predicts zero probability of tumor control. The minimum dose has a
major impact on the TCP and cold spots should be avoided.
The relative seriality model developed by Källman et al. (1992) handles normal
tissue that has mixed serial and parallel behavior. The model uses the ”relative
seriality” parameter s to describe the volume effect. This parameter s ranges from
low values for parallel types of tissue to high values for serial tissue. The NTCP is
expressed as
NTCPs(D) =
(
1−
M∏
i=1
(1− P (Di)s)
vi
Vref
)1/s
(22)
where vi/Vref is the relative volume of voxel i compared to the reference volume.
Paper III used this model, with the probability of response P (Di) calculated
with the Poisson-based linear-quadratic model (18), to estimate NTCP following
proton and photon irradiation in treatment plan comparison.
Another common NTCP model is the Lyman Kutcher Burman (LKB) mo-
del (Lyman, 1985; Kutcher and Burman, 1989). This model is the Lyman mo-
del (20) extended with a volume effect. The upper limit t of the integral in the
cumulative normal distribution is here instead expressed as
t =
D −D50(v/Vref)
mD50(v/Vref)
(23)
where
D50(v/Vref) = D50(1)
(
v
Vref
)−n
D50(1) denotes the dose giving 50% complication probability for uniform irradia-
tion of the whole organ and v/Vref is the volume fraction. n specifies the volume
dependence.
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Other models include the critical-element model (Niemierko and Gotein 1991),
critical volume model (Niemierko and Gotein 1993), parallel architecture model
(Jackson 1995), and Weibul distribution model (Klepper 2001).
Individual TCPs and NTCPs can be combined into composite probabilities.
The probability of complication-free tumor control, P+, is an attempt to combine
probabilities into a single measure of the overall quality of the treatment plan (Lind
et al., 1999):
P+(D) = TCP (D) (1 +NTCP (D)) (24)
Which NTCPs to be included into the P+ expression is essential. Failure to control
the tumor should not be balanced against the risk of minor normal tissue complica-
tions. Only the NTCP of severe complications should be considered to be included
in the calculation of P+.
Biologically equivalent doses
The vast majority of treatments with radiation therapy to date are performed using
photon beams. For decades, uniform intensity beams were used, fraction doses
around 2 Gy have been given, and treatment goals stated in terms of dose. To
take advantage of the vast experience gained from conventional radiation therapy,
non-standard photon doses and ion doses are converted to traditional photon doses
(rather than to biological outcome). The underlying assumption is that different
doses are equivalent if they cause the same biological effect. Another benefit of the
expressions of biologically equivalent doses is that they allow for direct comparison
of different treatment plans.
Equivalent uniform dose
The concept of the equivalent uniform dose (EUD) was proposed by Niemierko
(1997). The idea is that any dose distribution has a corresponding uniform dose that
causes an equivalent biological response. Originally EUD was defined for tumors
only and was based on survival fractions, but was later refined (Niemierko, 1999)
to apply also for normal tissues, in what is referred to as the generalized EUD:
EUD =
(
M∑
i=1
vid
a
i
)1/a
(25)
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where di denotes the dose in voxel i, vi is the fraction of the volume of interest
that is occupied by voxel i, M is the total number of voxels, and a (6= 0) is a
tissue specific parameter that controls the volume effect. As a→∞, EUD appro-
aches its maximum. For tissues where the biological effect is highly dependent on
maximum doses, i.e. serial tissues, a large positive a value is used so that larger
doses are given higher weight. As a = 1, EUD becomes the arithmetic mean dose,
and therefore parallel-structured organs have an a value close to unity. For tumors,
negative values are used so that cold spots have a large effect on the EUD.
Equivalent dose in 2 Gy fractions
The standard fractionation schedule of around 2 Gy per day for five days a week
is probably not optimal for all cases. EQD2, the equivalent dose in 2 Gy-fractions,
is used for example to compare fractionation schedules. It estimates the total dose
delivered in 2 Gy-fractions that would yield the same biological effect as the total
dose obtained using the fractionation schedule of interest. A general expression for
EQD can be derived from the LQ cell survival model (Eq. 4):
SLQ(D) = e
(∑n
k=1−αdk
(
1+
dk
α/β
))
= e
−αDref(1+ drefα/β ) = SLQ(Dref) (26)
where n is the total number of fractions. Dref is here the reference total dose that
give the equivalent effect, i.e., the EQD:
EQD =
∑n
k=1 dk
(
1 + dkα/β
)
1 + drefα/β
(27)
where dref denotes the reference fraction dose. If equal fraction doses dk are used
and dref = 2 Gy, this expression reduces to
EQD2 =
D
(
1 + dα/β
)
1 + 2α/β
. (28)
If two treatment plans with different fractionation schedules are to be compared
and both are rescaled using EQD2, the treatment plan with the highest EQD2 will
give more damage than the other plan, according to the model.
A closely related concept also used is the biologically effective dose (BED) (Barend-
sen, 1982; Dale, 1985; Jones et al., 2001; Fowler, 2010). The BED is defined as
BED =
−lnSLQ
α
= D
[
1 +
d
α/β
]
(29)
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where the expression in the brackets is the relative effectiveness (RE). By dividing
the BED with the RE of a reference radiation schedule, EQD is obtained.
Just as incomplete repair and repopulation can be incorporated into the LQ
model, these effects can also be accounted for in EQD and BED.
Relative biological effectiveness
Relative biological effectiveness is defined as the ratio of the dose of a reference
radiation, normally low-LET photons, and the corresponding ion dose giving the
same biological response under otherwise equal conditions:
RBE =
Dref
D
. (30)
It is a measure of the efficiency of producing a specific response by a radiation type
and provides a link between the dose of ions and the dose of photons. The physical
ion dose can be multiplied with the RBE to obtain a photon equivalent dose with
the unit Gy(RBE). It is essential that an appropriate RBE value is used since an
incorrect RBE value may propagate into inappropriately chosen ion prescription
doses, give a higher biological effect in normal tissues than intended, and hinder
correct plan comparison. RBE-models aim at estimating this relative biological
effectiveness.
The biological efficiency is generally higher for ions, but the efficiency has
been found to depend on various factors (Gerweck and Kozin, 1999; Kraft, 2000;
Weyrather and Debus, 2003). Since the RBE is defined relative to sparsely ionizing
radiation that often shows a non-linear response to dose, RBE depends on the dose
level. RBE increases with decreasing dose per fraction.
Another clear trend is that RBE varies with LET. With increasing LET the da-
mage becomes more severe and more difficult to repair resulting in higher radiation
lethality, and reflected by a higher RBE. However, there is a maximum after which
the effectiveness is reduced and RBE decreases. The RBE maximum appears at
LET values around 30 keV/µm for protons (Belli et al., 1998), but is shifted to gre-
ater LET values for heavier ions (Kraft, 2000). Thus, the biological effect varies
between ions at the same dose and LET. This is a result of differences of the dis-
tribution of ionizing events. Also the maximum RBE that can be obtained differs
between ions, with the higher LETs of carbon ions compared to protons translating
into higher maximum RBE.
Moreover, RBE varies between different cell and tissue types. Slowly prolife-
rating cells tend to yield larger RBE than fast proliferating cells, and cells with a
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high repair capacity give larger RBE than poorly repairing cells. RBE also varies
across endpoints.
In proton radiation therapy, the majority of therapy centers assume a constant
RBE value of 1.1 for all clinical situations regardless of the physical properties of
the proton beams and the biological system. The LET variation is relatively small
and therefore a constant RBE has been considered as an acceptable simplification.
For carbon ions, the RBE is higher and the variation is larger and, therefore, no
single RBE value is appropriate for every combination of factors affecting the RBE.
A general RBE-expression can be derived based on the LQ model (5) together
with the definition of RBE:
S = e−αd−βd
2
= e−αphotdphot−βphotd
2
phot = Sphot (31)
where d is the fraction dose, and all quantities with the subscript phot refer to
photon radiation while the others refer to ion radiation. By solving a second-degree
equation for the positive root, one obtains
dphot = −1
2
(
α
β
)
phot
+
√
1
4
(
α
β
)2
phot
+
α
βphot
d+
β
βphot
d2 (32)
The RBE at a certain ion dose d can then be expressed as
RBE (d) =
dphot
d
=
= − 1
2d
(
α
β
)
phot
+
1
d
√
1
4
(
α
β
)2
phot
+
α
αphot
(
α
β
)
phot
d+
β
βphot
d2
(33)
In paper II, we developed an RBE model specifically for protons based on
this expression. A parameterization by LET and cell type was incorporated. The
approach was to study the proton parameters α and β by investigating how α/αphot
and β/βphot varies with LET, for a set of experimental data. We then investigated
how this LET-dependence is affected by cell type as characterized by (α/β)phot.
Based on experimental in vitro data of a range of different cell types irradiated
with protons of well-defined dose and LET, the α/αphot was found to increase
with increasing LET with a slope inversely depending on cell type. However, no
statistically significant relation between β/βphot and LET was found and β for
protons was assumed to be equal to that of photons. The resulting RBE expression
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describes the RBE as a function of dose, LET, and (α/β)phot:
RBE
(
d, LET, (α/β)phot
)
= − 1
2d
(
α
β
)
phot
+
+
1
d
√√√√1
4
(
α
β
)2
phot
+
(
0.434LET +
(
α
β
)
phot
)
d+ d2
(34)
The model predicts a tissue-dependent relation between RBE and LET de-
termined by the (α/β)phot ratio: the RBE increases with increasing LET for cell
lines with low (α/β)phot ratio, but the relation becomes weaker with increasing
(α/β)phot, and at high (α/β)phot ratios, RBE is low and insensitive to LET changes.
Moreover, the model shows an increasing RBE with decreasing dose per fraction
and the effect is most pronounced for low (α/β)phot values.
This RBE model does not account for the decrease in RBE that occurs at LETs
higher than around 30 keV/µm. However, in clinical proton therapy that high LET
values are of little practical relevance.
Other RBE models include (Hawkins, 1998; Dale and Jones, 1999; Wilkens
and Oelfke, 2004; Tilly et al., 2005; Carabe et al., 2012; Frese et al., 2012).
Model selection and evaluation
Models are approximations of reality, and their predictions are subject to uncertain-
ty. Even when the input, such as absorbed dose and LET, is accurately described,
the output, such as survival fraction or NTCP, can have large uncertainties. Living
systems are complex, with individual heterogeneity, interactions, and environmen-
tal covariates, and radiobiological models can at best give good approximations.
However, the uncertainty in the output is not only due to limitations in how accura-
tely the model captures reality but also to uncertainties in its parameters, which are
estimated from limited empirical data. As George E. P. Box put it (Box and Draper,
1987): “All models are wrong, but some are useful”. To judge if a model is useful
it needs to be evaluated, and if there are a number of candidate models, methods
are needed to select the most useful one.
Parameter estimation
Once a model is specified, the parameters that give the best fit of that model to data
can be assessed through parameter estimation. Two well-known methods are least
squares estimation (LSE) and maximum likelihood estimation (MLE).
The method of least squares estimation is a standard approach in many natural
sciences and is linked to concepts such as root mean squared deviation, and coeffi-
cient of determination (r2). The best estimates of the parameters θ to data y given
a model f are those that minimizes the sum of squared error (SSE) - hence the
name of the method. Error here denotes the difference between the predicted and
observed value at each data point.
SSE(θ) =
∑
i
(yi − f(xi, θ))2 (35)
LSE makes no explicit assumptions of the probability distribution of observed
quantities.
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Maximum likelihood estimation is based on the probability density function
f(y | θ) that specifies the probability of observing the data y given the parameter
vector θ. The likelihood takes the inverse perspective: what is the likelihood of
the parameter θ given the observed data, L(θ | y) = f(y | θ). That is, under the
assumption of a given model, what parameter values yield the highest probability
for the observed data. In MLE the attempt is to find the parameter values that
make the observed data ”most likely”, i.e., that maximizes the likelihood function
L(θ | y). If individual data points yi are independent of each other, the likelihood
function can be expressed as
L(θ | y) =
∏
i
f(yi | θ) (36)
Maximizing the product is equivalent to maximizing the logarithm of the likelihood
lnL(θ | y) =
∑
i
lnf(yi | θ) (37)
Many model selection criteria such as the Akaike information criterion (AIC) (Aka-
ike, 1973), Baysian information criterion (BIC) (Schwarz, 1978), and Vuong’s test
(Vuong, 1989) are based on MLE.
In Paper IV, MLE was used to fit two dose-response models, a Poisson-based
linear model (17) and the Lyman model (20), to clinical outcome data. For each
study setting i, the outcome data was presented as the proportion of patients in
which the studied endpoint was detected giving a binomially distributed outcome.
The likelihood function was therefore expressed as
L(θ | N, cases) =
∏
i
P (Di, θ)
casesi (1− P (Di, θ))Ni−casesi (38)
where P (D, θ) denotes the probability of the adverse event at a given dose predic-
ted either by the Poisson-based linear model or the Lyman model, N denotes the
total number patients in the study, and cases denotes the number of occurrences of
the studied endpoint.
If the observations are independent and normally distributed with a constant
variance, LSE and MLE result in the same parameter estimates. Otherwise, diffe-
rent conclusions of the same observed data can be made depending on the method
used.
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Statistical hypothesis testing
Statistical hypothesis tests attempt to reject hypotheses based on observed data.
The research question is expressed as a null hypothesis, which states the opposite
of what we seek to show. The goal is to investigate if there is sufficient evidence
to reject the null hypothesis in favor of the alternative hypothesis. A statistically
significant result is one assessed as unlikely to have occurred by chance under the
null hypothesis. A threshold probability, called the significance level, is predefined
to determine how unlikely an observed result must be in order to be classified as
statistically significant.
The development of the RBE model for protons in Paper II was driven largely
by hypothesis tests. The significance level was consistently set to 0.05, and the
data consisted of experimentally obtained LQ parameter values from a range of
different cell lines irradiated with protons, and with photons as a reference. Our
first aim was to explore whether there exists a linear dependence between α/αphot
and LET
f(LET ) =
α
αphot
(LET ) = 1 + k · LET +  (39)
where  is assumed to be independent and normally distributed random errors. The
null hypothesis was that k equals zero. The test statistic for the slope of a linear
regression model is:
tk =
k − k0
SE(k)
(40)
which follows a tn−2 distribution if the null hypothesis is true. k is the estima-
ted slope based on the observations in the sample and k0 is the slope of the null
hypothesis. SE(k) denotes the standard error of the slope and can be computed as
SE(k) =
√
1
n−2
∑n
i=1 (yi − f(LETi))2√∑n
i=1
(
LETi − LET
)2 (41)
where y denotes the experimentally obtained α/αphot values, LET is the mean
LET, and n is the number of data points. If the test statistic tk is large i.e. if the
estimated slope is large compared to its standard error, then the null hypothesis is
rejected. We used the one-tailed t-test since we are interested in the hypothesis that
the slope k > 0, and obtained a p-value < 0.05 allowing us to conclude that the slope
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is statistically significantly greater than zero at this significance level, meaning that
there is a positive relation between α/αphot and LET.
The same procedure was performed to test if there exists a linear dependence
between β/βphot and LET. Here, the null hypothesis could not be rejected. In other
words, we did not find statistical support to include such a relation in our model.
In case of the intercept, it is often assumed to be 1 since the biological effecti-
veness of protons is assumed to approach that of photons as LET decreases. There
is no natural null hypothesis to test this assumption, so instead we constructed a
95% two-sided confidence interval for the intercept:
m± tm · SE(m) (42)
where the standard error of the intercept is expressed as
SE(m) =
√√√√ 1
n− 2
n∑
i=1
(yi − f(LETi))2 ·
√
1
n
+
LET
2∑n
i=1 (LETi − LET )2
(43)
The confidence interval included our assumed value of 1.
Model selection
Akaike information criterion
The Akaike information criterion (AIC) (Akaike, 1973) is a measure used for se-
lecting the best fitting model from a set of possible models. The models do not
need to be nested. AIC gives a relative estimate of the information lost when a
given model is used to approximate the ”true model”, that is, the unknown model
that generated the data of interest. Thus, the model that is closest to the true mo-
del, based on the expected Kullback-Leibler distance, is the one that minimizes the
information loss (Burnham and Anderson, 2002). The AIC is computed as
AIC = −2lnL+ 2K (44)
where L is the maximum likelihood estimate andK is the number of parameters in
the model. An AIC is computed for each candidate model and the preferred model
is the one with the lowest AIC value. Generally, the likelihood may be increased by
increasing the number of parameters, but the 2K term in the expression is effecti-
vely a penalty for extra parameters. Thus, this model selection technique balances
goodness of fit with model complexity.
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AIC selects the best model in the set of models considered. However, it does
not state if one model is significantly better than another or the quality of fit for any
of them.
Bayesian information criterion
The Bayesian information criterion (BIC) (Schwarz, 1978) is an alternative model
selection criterion. It is derived in a Bayesian setting and favors the model with
highest probability given the observed data. The form of BIC is closely related to
that of the AIC but with different penalty for model complexity
BIC = −2lnL+Klnn (45)
where n is the number of data points. In practice, BIC imposes a stronger penalty
for complexity. One advantage of BIC over AIC is that the probability of it se-
lecting the true model (if part of the considered set of models) approaches 1 as
sample size approaches infinity. The same is not true for AIC. On the other hand,
in finite samples BIC tend to choose too simple models (Hastie et al., 2009).
Vuong’s statistical test
Vuong’s statistical test (Vuong, 1989) is a likelihood ratio-based test for model
selection that can be used for non-nested models. The null hypothesis is that the
two models compared are equally close to the ”true” model, whereas the alternative
hypothesis is that one model is closer, where the ”closeness” is determined by the
expected Kullback-Leibler distance. Hence, the test not only ranks which model
is the most likely to generate the given data, but also determines if one model is
significantly better than another. Unlike for example AIC and BIC, it may conclude
that data does not strongly support one model over the other.
In Paper II, Vuong’s test was used to evaluate if the LET dependence in the
proposed RBE model is significantly influenced by the cell type, where the cell type
was represented by its α/β ratio of photons. The cell type was found to statistically
significantly influence the LET–RBE relation.
A test that was not reported in Paper II but will be shown here is whether on the
whole our developed RBE model for protons (model 1) gives a significantly better
fit to the experimental data used in the study than the standard assumption of RBE
equal to 1.1 (model 0). We assume normally distributed residuals  and obtain the
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likelihood for each model as
L =
∏
i
f(yi | θ) =
∏
i
1
σ
√
2pi
e−
2i
2σ2 (46)
The test statistic V is obtained as
V =
ln(L1)− ln(L0)− K1−K02 ln(n)√
nω2
(47)
where
ω2 =
1
n
n∑
i=1
ln
(
f1(yi | θ1)
f0(yi | θ0)
)2
(48)
and n is the number of data points. K1 and K0 are the number of parameters
in model 1 and 0, respectively. Vuong’s test statistic follows a standard normal
distribution, and the obtained value 3.24 corresponds to a two-tailed p-value equal
to 0.001, indicating a stongly significantly better fit of the RBE model developed
in Paper II than for the assumption of RBE equal to 1.1.
Resampling techniques
An alternative class of methods to estimate the precision and predictive value of a
model on new data are resampling techniques. They attempt to mimic the process
of new data generation, by drawing modified samples from the sample at hand.
Bootstrapping
Bootstrapping is a resampling technique first introduced by Efron (1979) that re-
lies on sampling with replacement from the sample at hand, often using Monte
Carlo methods. Traditionally, when one wants to draw conclusions about an aspect
of an unknown population, inference requires assumptions about the distribution
of the underlying data. The bootstrap analogy and fundamental assumption is that
sampling with replacement from the original sample mimics the process of samp-
ling from the underlying population. Thereby, the bootstrap eliminates the need to
make strong assumptions about the distribution, such as normality. Instead, the as-
sumption is that if the observed data is a representative sample of the population,
conclusions can be made of the population by studying the sample. The bigger the
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Figure 5: The bootstrap method. I: From the original incidence data given as the
fraction of occurrences of the side effect of the total number of patients, an esti-
mated dose-response relation can be obtained. II: Through sampling with replace-
ment, plausible alternative outcomes at each dose are simulated. To each bootstrap
replicate a dose-response curve is fitted. III: The resulting range of dose-response
curves and model parameters visualizes the uncertainty due to sample variability.
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original sample, the more likely it is to adequately reflect the nuances of the un-
derlying population. Bootstrapping can be used for several purposes such as esti-
mation of sampling variability, construction of (asymmetric) confidence intervals,
and model selection.
From the observed data of sizeN , a new sample of the same sizeN is randomly
drawn with replacement. Due to the replacement, each original data point may or
may not be drawn and may be drawn more than once. This generates a bootstrap
sample somewhat different from the original one. From this bootstrap sample some
quantity of interest, such as the mean of a particular variable, a parameter estimate,
or the goodness-of-fit, can be obtained and stored. The procedure is repeated to
generate a large number (e.g. 10 000) bootstrap samples, and for each new sample
the statistic of interest is computed. This provides a bootstrap distribution of the
statistic from which standard errors, confidence intervals etc. can be obtained.
In Paper IV, a bootstrap method was proposed to assess the uncertainty of the
outcome after irradiation of the lung (end point: pneumonitis) and spinal cord (end
point: myelopathy). The data studied was obtained from the Quantitative Analysis
of Normal Tissue Effects in Clinic (QUANTEC) review (Kirkpatrick et al., 2010;
Marks et al., 2010). The QUANTEC report provides a summary of dose-response
data for many types of normal tissue. Since the dose-response relations are esti-
mated from limited numbers of patients, and recommendations of normal tissue
constraints for radiation therapy are based on these relations, it is important to
quantify the associated uncertainty. In Paper IV, the uncertainty due to sample va-
riability was assessed. The QUANTEC report provides the number of patients, Ni,
that received a certain dose to the organ studied, and how many of them experi-
enced a certain side effect, in a particular study setting i. 10 000 bootstrap samples
of the same sizeNi as in the original data were produced by random sampling with
replacement within each setting. For each bootstrap sample, the number of occur-
rences of the side effect was obtained. The result is a range of incidence estimates
for a given dose. The procedure was repeated for all doses in the outcome data.
Two dose-response models, a Poisson-based linear model (17) and the Lyman
model (20), were fitted to each bootstrapped dose-response relation using max-
imum likelihood estimation. The result is 10 000 dose-response curves for each
model and as many sets of parameter values. The spread in the dose-response cur-
ves and parameter values reflect the uncertainty due to sample variability. An il-
lustration of the bootstrap method is shown in Figure 5.
A 95% pointwise confidence band around the mean dose-response relation was
obtained by ordering the model-based probability estimates for each dose unit and
identifying the values at the lower and upper 2.5 percentiles.
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Figure 6: Dose-response curves for pneumonitis accounting for inter-experimental
variation with 95% confidence interval (blue dashed lines). For comparison, the
95% confidence interval accounting only for variability within the studies are
shown (red dashed lines).
The bootstrap method was used in Paper IV also for model selection. By com-
paring the maximum likelihood of the two dose-response models for each bootstrap-
ped data set, the model selection relative frequencies can be determined. The mo-
del most often giving the best fit is considered the best. The Lyman model achieved
higher maximum likelihood than the Poisson-based model in over 90% of the times
for the outcome data of both spinal cord and lung. If the models to be compared
have different number of parameters, AIC can be used as the criterion of selection
instead of MLE.
The bootstrap analysis used in Paper IV was conditioned on the set of study
settings in the original sample. Thereby, it resampled only the number of occur-
rences for each setting. Instead, one could have first resampled the study settings,
and then resampled patients within each randomly drawn setting. This would re-
flect an additional source of variability – the composition of experimental settings
in the original set of studies. The resulting range in dose-response curves is wider
with this approach since it accounts both for variations within each experiment but
also inter-experimental variation as shown in Figure 6. The method still provides a
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lower limit on the total uncertainty since uncertainties in the delivered dose etc are
not accounted for.
Cross validation
Cross validation is a model evaluation technique used to test a model’s predictive
ability on independent data. Predictive models require a proper trade-off between
bias and variance, or with other words, between underfitting and overfitting to the
data at hand. A model may give an accurate fit to the data it was fitted to but fail
to perform on independent data from the same population. Too many parameters
compared to the amount of data will generally result in a model with poor predicti-
ve power on new data. The result of overfitting is a model that describes random
error or noise rather than the underlying relation.
A basic approach to test the generalization performance is to divide the data
into a training set, to which the model is fitted, and a test set, against which the
model is evaluated. This is referred to as hold-out testing. In Paper I, this approach
was used to test the robustness of the developed LET-parameterized RCR model.
The model was fitted to a subset of the cell survival data, and the model parameters
estimated from this subset were subsequently evaluated against the excluded data.
We found that the cell survival curves of the lowest LET, the highest LET, and
the most effective LET for cell inactivation (at RBE maximum), could be used to
predict the cell survival curves of all other LETs. In this study, the main interest was
to evaluate the LET dependence of the model, and survival curves of pre-specified
LETs were omitted in the robustness test. Another way of leaving data out would
have been to randomly exclude individual data points from the cell survival data.
A problem with the hold-out method is that it is inefficient when the data set is
small. The partitioning of the data results in less data available for building the mo-
del and can make the data set too small for accurate training. The hold-out method
can be improved by repeating the process with different subsamples in so-called
cross validation. In k-fold cross validation, the data is randomly divided into k
subsets of equal size. k-1 subsets are pooled to form a training set and the remai-
ning one is used for validation. The process is repeated k times with a different
subset held out in each iteration. A special case of k-fold cross validation is when
k equals the number of data points in the data. This method is called leave-one-out
cross validation. A common choice is 10-fold cross validation. In the end, k values
of the quantity used to measure performance are available, which can be averaged
to obtain an aggregate measure. These measures can be used for model selection
between competing models.
Treatment planning using
biologically-based models
The aim in curative radiation therapy is to obtain local tumor control with high pro-
bability without too high risk of unacceptable side effects. In treatment planning,
the clinical goals are instead usually stated indirectly in terms of physical quan-
tities such as prescription dose and dose-volume limits to normal tissue. These
quantities are used as surrogates of biological outcome instead of using estimates
of biological outcome directly. An advantage of biological models is the more in-
tuitive character which makes it easier to compare with clinical outcome, and that
they more easily allow for including also the patient’s own priorities in weighting
different outcome probabilities.
The long use of radiation in the treatment of cancer has resulted in established
clinical experience of the relation between dose and outcome for standard treat-
ments. For example, keeping a maximum dose below a certain dose level to an
organ has been correlated with an acceptable risk of side effects. Radiobiologi-
cal models aim to capture this experience and make it explicit with mathematical
expressions. Instead of threshold values, implying that an effect occurs above the
stated criteria but not below, biologically-based metrics may provide continuous
estimates of outcome probabilities. Since dose-volume based criteria only control
a single point in the DVH, often several functions are required for an organ, and
individual priorities between these may be needed. Biologically-based cost func-
tions have the advantage that they comprise the entire dose distribution and provide
an inherent prioritization of the dose-volume domain. Biological models are also
useful in plan comparison. It can be difficult to judge and order different plans only
based on dose distributions and DVHs.
Biological models are valuable for standard treatment but are even more nee-
ded when deviations from the intended treatment are made. If the treatment of a
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Figure 7: The left panel shows the dose distribution of the total dose (Gy) for the
IMRT plan, and the right panel shows the RBE-weighted dose distribution for the
IMPT plan accounting for a variable RBE. The arrows show beam angles.
patient is changed for some reason, for example dose fractions are missed due to
the patient being absent or the treatment machine going down, the total dose can-
not be used alone to determine the outcome. Another scenario is that deviations
from the intended dose distribution, due to organ motion or tumor shrinkage, are
detected from imaging during the course of treatment. Biological models are then
needed to calculate how to compensate for the deviations. For protons, and even
more so for carbon ions, the dose alone is even more difficult to use as a predictor
for outcome.
In Paper III, two treatment plans for a brain tumor case were compared (see
Figure 7). The tumor was located close to critical organs such as the brain stem
and optic nerve. Both plans were created using intensity modulated beams, one
using photons (IMRT) and one using protons (IMPT). Since equal physical photon
and proton doses do not give equal biological effect, a plan comparison based on
doses cannot be made directly. In this study, the proton dose was converted to a
biologically equivalent photon dose using RBE. In the optimization of the proton
plan, a standard constant RBE equal to 1.1 was assumed. In the plan evaluation,
both a standard RBE of 1.1 and an RBE distribution calculated using the RBE-
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model (34) developed in Paper II were used to weight the physical dose obtained
in the plan creation.
Figure 8: The left panel shows the difference in equivalent doses between the IMPT
plan and the IMRT plan under the standard assumption of RBE equal to 1.1 (proton
RBE1.1-weighted dose - photon dose). The right panel shows the dose difference
when accounting for variable RBE.
The plan comparison showed that considerably lower equivalent doses to nor-
mal tissues were generally obtained with protons compared to photons regardless
of the RBE assumed. However, the DVH revealed so called hot spots, high doses
in small volumes, in the proton plan. Even with the knowledge that brain stem and
optic nerve are serial organs where the highest doses to a high extent determine the
outcome, it is difficult to know where trade-off lies. How ”hot” do the hot spots
in an organ need to be to override the favorable low doses everywhere else? The
NTCP model (22) used predicts that the very limited hot spots in for example the
brain stem estimated with an RBE equal to 1.1, did not overcome the much lower
dose to this organ in general compared to the plan obtained with photons. A lower
NTCP was estimated in the proton plan compared to the photon plan. In contrast,
when a variable RBE was accounted for, the hot spots generated a predicted worse
NTCP for the brain stem with protons compared to photons, despite the otherwise
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much lower dose.
For the tumor, a somewhat higher biological equivalent dose in the tumor was
obtained with protons compared to photons under the assumption of RBE equal to
1.1, whereas the opposite was obtained under the evaluation accounting for RBE
variation. Figure 8 show the difference in equivalent doses between protons and
photons calculated using both RBE equal to 1.1 and a variable RBE. In conclusion,
the RBE model predicts a disadvantageous trend with lower biological effect in
the tumor (high α/β) and higher effect in late-responding normal tissue (low α/β)
than expected from the standard assumption of a constant RBE equal to 1.1.
In the study presented in Paper III, the plans were optimized based on dose
and dose-volume functions with an assumed RBE equal to 1.1. Only the evaluation
was based on biological models. If the plans were optimized using also biological
models, possibly a better proton plan could have been obtained.
Models describing the relationship between dose, irradiated volume and tis-
sue response are associated with uncertainties because of the difficulty to precisely
assess the reaction of tumors and surrounding normal tissues to radiation. These
uncertainties and model limitations have so far restricted the application of biolo-
gically based optimization methods in clinical radiation therapy. Today, biological
models can be useful in optimizing and evaluating treatment plans, but should not
be relied upon uncritically. Especially not if they suggest non-standard treatments.
Instead biological and physical criteria should be used together.
Summary of papers
Paper I: Analytical description of the LET dependence of
cell survival using the repairable-conditionally repairable
damage model
Paper I is co-authored with Bengt K. Lind, Iuliana Toma-Dasu, Henrik Rehbinder,
and Anders Brahme, and has been published in Radiation Research, Vol. 174, pp.
517-525, 2010.
In this paper, we extend the repairable-conditionally repairable (RCR) damage
model by including an LET-parameterization to provide a radiobiological model
for ions that accounts for both dose and LET. The LET dependence is incorporated
by expressing the model’s parameters as functions of LET. These expressions are
derived so that the model agrees with expected biological mechanisms.
The model was found to fit published cell survival data irradiated with helium
ions and carbon ions for LETs ranging up to LETs high enough to observe a redu-
ced effectiveness in cell inactivation per unit dose, the so-called overkill effect. The
model’s ability to predict unseen experimental data using only a limited subset of
the experimental data was evaluated, and the excluded data could indeed be recre-
ated. The fraction of cells being damaged decreases at high LETs for a constant
dose level, which could be explained by a clustering of damage in some cells at
the expense of other cells being non-hit, and the normalized fraction of cells being
repaired decreases with increasing LET.
By expressing the parameters as functions of LET instead of having these pa-
rameters free, and by fitting the cell survival curves of all LETs simultaneously
instead of making an individual fit for each LET, a somewhat less accurate fit to
the data is obtained. The gain is the generalization that opens up the possibility of
estimating cell survival also for dose and LET combinations for which we have no
experimental data available.
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Paper II: A model for the relative biological effectiveness
of protons: The tissue specific parameter α/β of photons is
a predictor for the sensitivity to LET changes
Paper II is co-authored with Bengt K. Lind and Björn Hårdemark, and has been
published in Acta Oncologica, Vol 52, pp 580-588, 2013.
In this paper, we propose a model for the relative biological effectiveness (RBE)
of protons where RBE variations due to LET, dose, and cell type are accounted for.
The RBE model is based on the linear-quadratic model, and the cell type is repre-
sented by the (α/β)phot ratio of the reference photon radiation. Published α and
β parameters of the LQ model obtained after proton irradiated were studied with
respect to their dependence of LET. Clonogenic cell survival data of ten different
cell lines irradiated with near monoenergetic proton beams with LET values ran-
ging from 6 to 30 keV/µm was selected.
A statistically significant positive relation betweenα/αphot and LET was found.
However, upon a closer examination, it was the cell lines with low (α/β)phot that
contributed to the positive slope. The slope was found to vary statistically sig-
nificantly with (α/β)phot. No statistically significant relation was found between
β/βphot and LET.
The proposed model predicts a cell-dependent relation between RBE and LET
determined by the (α/β)phot ratio: RBE increases with increasing LET for cell
lines with low (α/β)phot ratio, but the relation becomes weaker with increasing
(α/β)phot, and at high (α/β)phot ratios, RBE is low and relatively insensitive to
LET changes. This implicates that late-responding tissues are more sensitive to
high LETs than early-responding tissues and most tumors. Moreover, the model
shows an increasing RBE with decreasing dose per fraction in a cell-dependent
way, where the effect is most pronounced for low (α/β)phot.
In conclusion, the (α/β)phot ratio describing the sensitivity of cells to photon
radiation, is a predictor also for the sensitivity to proton radiation. The highest RBE
values are predicted for cell lines with low (α/β)phot receiving high LET and low
dose per fraction.
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Paper III: Disregarding RBE variation in treatment plan
comparison may lead to bias in favor of proton therapy
Paper III is co-authored with Iuliana Toma-Dasu, and has been submitted for pub-
lication.
In this study, the aim is to investigate how the comparison of treatment plans
created using photons and protons is affected by accounting for a variable RBE.
When comparing treatment plans of protons and photons, the increased effective-
ness of protons per unit dose has to be taken into account and biologically equi-
valent doses should be used. The conversion from a physical proton dose into an
equivalent photon dose is made by the concept of RBE. In clinics today, the RBE
is usually assumed to be constant and equal to 1.1. However, proton RBE has ex-
perimentally been found to depend on various factors. In this study, the effect of
disregarding RBE variations is evaluated.
Two intensity modulated treatment plans, one using photons (IMRT) and one
using protons (IMPT), were created for the same patient. In this brain tumor case
the tumor is located close to the brain stem and optic nerve. The proton plan was
optimized with a standard RBE equal to 1.1 with the aim to produce a plan giving
as high dose to the tumor as the photon plan or higher while limiting the dose to
normal tissues to be as low as in the photon plan or lower. In the plan compari-
son, a variable RBE was accounted for. The RBE model developed in Paper II was
used. To calculate an RBE distribution, the LET distribution is needed. The LET
calculation was implemented in the Monte Carlo dose engine framework for pencil
beam scanning in the treatment planning system RayStation (RaySearch Laborato-
ries, Stockholm, Sweden). For each voxel, the contributions from all protons were
scored, and a dose averaged LET was calculated.
Under the assumption of RBE equal to 1.1, higher equivalent doses to the tumor
were obtained for the proton plan compared to the photon plan while the equivalent
dose to the normal tissues was lower. In contrast, when accounting for RBE vari-
ations, the comparison showed lower equivalent doses to the tumor and hot spots
in organs at risk in the proton plan. These hot spots resulted in higher estimated
NTCPs in the proton plan compared to the photon plan under the assumption of
variable RBE. Disregarding RBE variations, might lead to a lower effect in the tu-
mor and a higher effect in normal tissues than expected. This trend may lead to
bias in favor of proton therapy in the comparison with photon therapy.
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Paper IV: Assessing the uncertainty in QUANTEC’s
dose-response relation of lung and spinal cord with a
bootstrap analysis
Paper IV has been accepted for publication in International Journal of Radiation
Oncology, Biology, Physics.
Dose-response relations are typically estimated from limited numbers of pati-
ents, rendering the relation uncertain. In this paper, we apply a bootstrap method to
assess the uncertainty of estimated population-based dose-response relations due
to sample variability.
Two clinical dose-response relations presented by QUANTEC, myelopathy of
the cervical spinal cord and pneumonitis, were studied. The bootstrap method ge-
nerates a range of plausible outcome probabilities by random sampling with repla-
cement from the original incidence data. The uncertainty in the clinical outcome
data was translated into an uncertainty in the dose-response relation described by
two commonly used models: the Poisson-based model and the Lyman model.
A 95% confidence interval for the mean dose-response was created as well as
a 95% confidence area of the resulting model parameter distribution. The Lyman
model showed a steeper slope than the Poisson-based model, and the model pa-
rameter pairs indicated correlation and non-Gaussian distribution. The bootstrap
model selection method preferred the Lyman model over the Poisson-based model.
The Lyman model had higher likelihood in over 90% of the bootstrap replicates in
both the lung case and the spinal cord case.
In conclusion, the proposed bootstrap method enables statistical analysis of
the uncertainty of the estimated dose-response relations based on the variability
inherent in the incidence data from which they are derived.
Conclusions and outlook
In this project, two mathematical models for biological effect estimation for ions
have been developed. In Paper I, the RCR cell survival model was extended to
account for LET. The LET-parameterized RCR model was found to be applicable
for estimating experimental cell survival data obtained from irradiation with carbon
ions and helium ions. The model predicts a decreasing survival probability with
increasing LET, but also accounts for the lower efficiency for further increased
LET, the overkill effect. The analytically expressed LET dependence allows for
predictions of survival probability for dose-LET combinations for which there is
no experimental data, and facilitates optimization.
The second model was developed specifically for protons and estimates the
RBE based on dose, LET, and cell type. The proposed model predicts a cell-
dependent relation between RBE and LET determined by the α/β ratio of photons.
In general, RBE increases with increasing LET, but the strength of the relation
decreases with increasing α/β. The highest RBE values are predicted for cell lines
with low α/β receiving high LET and low dose per fraction. The model was found
to provide adequate fit to experimental RBE data obtained at 2 Gy photon dose for
various cell types and LET values.
The derived RBE model was applied to a realistic treatment scenario. The mo-
del predicted a lower RBE than the commonly assumed value of 1.1 in the brain
tumor studied, and higher RBE than 1.1 in critical organs close to the tumor. As
a consequence, a treatment plan derived under the assumption of an RBE equal to
1.1 gave lower than expected effect in the tumor and higher than expected effect in
normal tissue, provided that the trends of our model are correct. We showed that
disregarding RBE variation may lead to bias in favor of proton therapy in compa-
rison to photon therapy.
Different methods for evaluating radiobiological models have been proposed
and used. A hold-out method was used in Paper I to test the ability of the LET-
parameterized RCR model to estimate survival curves for excluded LETs. Statisti-
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cal hypothesis tests, including Vuong’s test, were used in Paper II in the develop-
ment of the RBE model. In Paper IV, a bootstrap method was proposed to evaluate
two dose-response models: the Lyman model and a Poisson-based model. With
the current amount of clinical toxicity studies, typically with limited number of
patients included in each, sampling variability is of fundamental importance. The
uncertainty of the empirically derived biological models must be acknowledged
and accounted for in their application. The proposed bootstrap framework provi-
des a generally applicable method to evaluate the uncertainty of radiobiological
models due to sampling variability. The method provides confidence intervals of
the dose-response relation, model parameter values with confidence intervals and
their interrelation, and can be used for model selection.
This thesis makes contributions to the methodology for biological effect esti-
mation with mathematical models. Ultimately, these models could assist in the
search for optimal treatment plans. A specific challenge for research and method
development in this area is the limited amount of available data. Model develop-
ment and evaluation requires good and abundant empirical data. An important pri-
ority for the future should be to collect data and ensure that it can be shared within
the research community. More detailed data should be presented in scientific pub-
lications, in order that the results can be reproduced and re-evaluated. Specifically,
effective use of methods such as the bootstrap requires access to the original data
points; sample means and variances do not suffice.
Radiobiological models can potentially direct optimization toward clinically
advantageous treatments, but the uncertainties of the models and their parameters
have so far restricted their use. In Paper IV, the uncertainty due to sampling variabi-
lity was assessed and applied to dose-response relations, and confidence intervals
for model parameters were derived. With information about the full dose distri-
bution, the same approach could be used to estimate the uncertainty of predicted
dose-volume effects. A step forward in biology-based treatment planning would
be to account for uncertainties in model parameters by incorporating them into ob-
jective functions for robust optimization. In this way, conservative predictions of
clinical outcome probabilities, such as worst case scenarios, could be produced.
To utilize the full potential of protons in radiation therapy, treatment plans
should be optimized not only based on dose distribution, but also based on LET.
Biological models are needed in order to do so, since the dependence between bio-
logical effect and LET varies with the type of tissue. The impact of the RBE model
developed in Paper II on treatment plan comparison was evaluated in Paper III. A
natural next step would be to implement the RBE model into a treatment planning
system for use in treatment plan optimization.
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